Introduction
============

As is known to all, cancer is a common life-threatening disease. According to recent studies, the incidence of cancer increases 1% per year in Europe.[@b1-ott-9-3113] Among the adult population, a rising trend is reported for soft tissue sarcoma.[@b2-ott-9-3113] Breast, colorectal, prostate, and lung cancers are the most common oncological cause for death among the European population.[@b3-ott-9-3113] Cancer cannot be cured, as expected, due to the limited knowledge of iatrotechnique. So, exploration of more precise bio-indicators is valuable for early diagnosis of cancer and improving prognosis of patients.

Cell surface carbohydrates are involved in various biological processes such as cellular differentiation, maturation, proliferation, and malignant transformation.[@b4-ott-9-3113] Dramatic changes of cell surface carbohydrates are associated with cancer occurrence, tumor invasiveness, and metastatic behavior.[@b5-ott-9-3113] Sialyl Lewis X (sLe^X^) (NeuNAcα2,3Galβ1,4\[Fucα1,3\] GlcNAc), a carbohydrate antigen, is related to cell adhesion and our previous study showed that inhibition of sLe^X^ synthesis leads to decreased adhesion of trophoblast cells to endometrial epithelial cells.[@b6-ott-9-3113] Also, sLe^X^ is frequently expressed in human cancer cells and primary tumors.[@b7-ott-9-3113],[@b8-ott-9-3113] As a ligand for E-selectin and L-selectin, sLe^X^ is related to cell adhesion.[@b9-ott-9-3113] It has been demonstrated that sLe^X^ was involved in the adhesion of tumor cells to vascular endothelium.[@b10-ott-9-3113] The potential role of sLe^X^ in the tumor metastatic process has been supported by several clinical studies.[@b11-ott-9-3113]--[@b14-ott-9-3113]

Many studies have identified the relationship between sLe^X^ and cancer prognosis, but individual studies of the influence of sLe^X^ expression in cancer have failed to provide conclusive results. The present meta-analysis was conducted to further explore the relationship between sLe^X^ expression and cancer prognosis and clinicopathology.

Materials and methods
=====================

Publication search
------------------

We searched published studies in the PubMed and Embase databases up to May 2014 with the following search terms: (slex OR sialyl lewis x) AND (cancer OR neoplasms OR carcinoma OR tumor) AND prognosis. Furthermore, reference lists of main reports and review articles were also reviewed to identify additional relevant publications. The study was conducted and reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.

Selection criteria
------------------

Two authors (YL and JXL) reviewed the retrieved titles and abstracts to discriminate the eligible studies for inclusion in our meta-analysis independently. Published studies were included based on the following criteria: 1) written and published in English; 2) patients with cancer diagnosis by pathology; 3) studies about sLe^X^ expression in cancer tissues; 4) sLe^X^ expression was measured by immunohistochemistry (IHC) method; 5) full length paper with sufficient data on sLe^X^ expression and prognosis and prognosis-related factors; 6) we could find the full text. We excluded studies with the following criteria: 1) written and published in a language other than English; 2) studies about cell lines and animals; 3) studies about sLe^X^ expression in serum; 4) review articles without original data; 5) a commentary, letter to the editor, or monograph.

Data extraction
---------------

Two authors (YL and WG) performed the data evaluation independently. The following data were extracted from each study: the first author's last name; publication year; country; cancer source; number of patients; number of sLe^X^ expressions (positive/negative); clinicopathological factors (age, sex, tumor size, histological differentiation, lymphatic invasion, venous invasion, T/N/M stage, tumor stage, and recurrence); survival analysis.

Data synthesis and statistical analysis
---------------------------------------

Expression of sLe^X^ was analyzed as dichotomous variables, as positive expression versus negative expression. The clinicopathological factors were also conducted as dichotomous variables, as older age versus younger age for age; male versus female for sex; large versus small for tumor size; high versus low for histological differentiation; I and II versus III and IV for tumor stage; pT2 versus more than pT3 for depth of invasion (T stage); with versus without for lymphatic invasion, venous invasion, lymph node metastasis (N stage), distant metastasis (M stage), recurrence. Survival of sLe^X^ expression was analyzed by Cox's regression analysis conducted as hazard ratio (HR) and 95% confidence interval (95% CI). The data of expression of sLe^X^ and clinicopathological factors or survival rate were extracted and calculated by initial data of studies. These data were analyzed with random-effect method, and were measured in relative risk (RR) with 95% CI. Statistical heterogeneity was estimated by means of Cochran's Q test and *I*^2^ test. The *I*^2^ test represents the percentage of variation to heterogeneity, which is categorized as low (0%--40%), moderate (40%--60%), high (60%--90%), very high (\>90%). Subgroup analyses were carried out based on cancer or country of the included studies if a significant heterogeneity was found in overall meta-analysis. To identify any potential publication bias, we used Begg's test. All statistical analyses were performed with Review Manager 5.2 and STATA 12.0.

Results
=======

Systematic review
-----------------

We identified 178 studies that fit our search strategy, 41 studies were identified in our primary search ([Figure 1](#f1-ott-9-3113){ref-type="fig"}). Finally, 29 studies published between 1993 and 2013 were included in our meta-analysis.[@b11-ott-9-3113],[@b12-ott-9-3113],[@b14-ott-9-3113]--[@b40-ott-9-3113] Detailed characteristics of these studies are provided in [Table 1](#t1-ott-9-3113){ref-type="table"}.

Association of sLe^X^ expression with cancer prognosis and clinicopathology
---------------------------------------------------------------------------

sLe^X^ expression correlated with prognostic factors, including lymphatic invasion (lymphatic invasion versus non-lymphatic invasion) (pooled RR =1.36, 95% CI: 1.15--1.61, *I*^2^=62.3%), venous invasion (venous invasion versus non-venous invasion) (pooled RR =1.41, 95% CI: 1.18--1.67, *I*^2^=52.9%), T stage (pT3--4 stage versus pT2 stage) (pooled RR =1.14, 95% CI: 1.04--1.27, *I*^2^=59.6%), N stage (lymph node metastasis versus non-lymph node metastasis) (pooled RR =1.46, 95% CI: 1.29--1.66, *I*^2^=55.1%), M stage (distant metastasis versus non-distant metastasis) (pooled RR =1.76, 95% CI: 1.34--2.31, *I*^2^=42.1%), tumor stage (stage III/IV versus stage I/II) (pooled RR =1.42, 95% CI: 1.19--1.68, *I*^2^=69.9%), tumor recurrence (recurrence versus non-recurrence) (pooled RR =2.92, 95% CI: 2.02--4.23, *I*^2^=0.0%) ([Figure 2A](#f2-ott-9-3113){ref-type="fig"}).

Meantime, we found that sLe^X^ overexpression was not significantly related to cancer prognosis and clinicopathology factors, including age (older versus younger) (pooled RR =1.08, 95% CI: 0.97--1.21, *I*^2^=0.0%), sex (male versus female) (pooled RR =0.97, 95% CI: 0.88--1.07, *I*^2^=47.0%), tumor size (larger versus smaller) (pooled RR =1.23, 95% CI: 0.94--1.62, *I*^2^=51.1%), tumor differentiation (lower differentiation versus higher differentiation) (pooled RR =0.94, 95% CI: 0.72--1.21, *I*^2^=75.1%) ([Figure 2B](#f2-ott-9-3113){ref-type="fig"}).

sLe^X^ overexpression on cancer survival
----------------------------------------

Eight studies analyzed the overall survival (OS) of human cancer with positive/negative sLe^X^ overexpression, the HRs ranged from 2.42 to 9.10.[@b18-ott-9-3113],[@b30-ott-9-3113],[@b32-ott-9-3113],[@b34-ott-9-3113]--[@b36-ott-9-3113],[@b38-ott-9-3113],[@b39-ott-9-3113] The summarized HR of negative versus positive was 3.11 (95% CI: 2.25--4.32) with low heterogeneity (*I*^2^=0.0%) ([Figure 3](#f3-ott-9-3113){ref-type="fig"}).

Subgroup analyses
-----------------

We chose subgroup analyses in meta-analysis with relative high heterogeneity (*I*^2^\>40%). In subgroup analyses, studies were stratified by cancer category (colorectal cancer, gastric cancer, lung cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, oral squamous cell carcinoma, gallbladder cancer, pancreatic ductal adenocarcinoma, prostate cancer, and extrahepatic bile duct carcinoma) or ethnicity (Asia, America, and Europe). In addition, most of these analyses showed low heterogeneity after stratification ([Tables 2](#t2-ott-9-3113){ref-type="table"} and [3](#t3-ott-9-3113){ref-type="table"}).

Publication bias
----------------

Begg's test was created for assessment of possible publication bias. It suggested that publication bias had little influence on these meta-analysis results (*P*\>0.05) ([Figure 4](#f4-ott-9-3113){ref-type="fig"}).

Discussion
==========

The cancer statistics of the USA, in 2013,[@b41-ott-9-3113] clearly indicated that the methods of treatment for cancer need to be improved. Exploring new molecular biological prognostic and predictive markers is a hot topic in modern medicine. Nakagoe et al first reported that sLe^X^ was expressed in serum of patients with gastric and colorectal cancer as a tumor-associated carbohydrate antigen, which was also proven by clinicopathological and immunohistochemical studies.[@b42-ott-9-3113] The relationship between sLe^X^ expression and cancer prognosis was identified by a number of studies, which did not show conformable results. To our knowledge, this is the first meta-analysis that systematically evaluates the relationship between sLe^X^ expression and cancer prognosis and clinicopathology.

In the present study, a combined analysis of 29 articles (3,253 cancer patients) which showed the detection of high sLe^X^ expression in tumor tissues with poor prognosis outcome in cancer patients was conducted. Our results indicated that sLe^X^ expression was significantly correlated with lymphatic invasion, venous invasion, deep invasion (T stage), lymph node metastasis (N stage), distant metastasis (M stage), tumor stage, tumor recurrence, and OS. On the other hand, although a high level of sLe^X^ expression was found in patients like the elderly, females, or patients with large size tumor and high differentiation, these results did not show any significance.

What makes sLe^X^ overexpression account for the poor prognosis in cancer? By chemical analyses, it was shown that sLe^X^ oligosaccharide was the minimal structure binding to E-, L-, and P-selectin,[@b43-ott-9-3113] which was closely involved in the interaction between the endothelium and cancer cells. sLe^X^ is most commonly found in malignant tumors and plays a key role in cancer stem cell metastasis, hypoxia, and TNF-α, and promotes tumor adhesion, invasion, and metastasis by upregulating the sLe^X^ expression in the tumor microenvironment.[@b44-ott-9-3113]--[@b46-ott-9-3113] In the present meta-analysis study, we also found that sLe^X^ expression was correlated with tumor recurrence. On the other hand, it is widely accepted that expression of cell surface carbohydrates is altered during malignant transformation and tumor progression, and may influence determination of metastatic behavior of tumor cells.[@b21-ott-9-3113],[@b47-ott-9-3113] It has been identified that sLe^X^ was a terminal tetrasaccharide moiety present on numerous membrane glycoproteins and glycolipids of epithelial and lymphatic cells.[@b28-ott-9-3113] With such characters, a high level of sLe^X^ contributes to cell adhesion, metastasis, and invasion because the cell surface antigens can combine with other cells directly. sLe^X^ in conjunction with mucins, promotes cellular motility, thus contributing to tumor cell spreading and metastasis.[@b11-ott-9-3113],[@b48-ott-9-3113] Furthermore, sLe^X^ is expressed on granulocytes and monocytes which mediates inflammatory extravasation.[@b49-ott-9-3113],[@b50-ott-9-3113] However, the molecular biological mechanisms of how sLe^X^ overexpression affects the cancer prognosis are complicated and still need further exploration. For the first time, our meta-analysis study revealed that sLe^X^ could be a potential biomarker for poor cancer prognosis.

Due to the differences in nationality and cancer types which could cause heterogeneity among the studies, we conducted a subgroup analysis. In the subgroup analysis, the sLe^X^ overexpression may play different roles caused by differentiation, venous invasion, T stage, M stage, tumor stage, and sex factors among different types of cancers. These factors contribute to the possible presence of heterogeneity between the studies. The difference might be owing to the molecular biological mechanisms of interactions between sLe^X^ overexpression, and the occurrence and development of different types of cancers. Otherwise, ethnicity may be another factor that contributes to heterogeneity in sex, tumor size, differentiation, venous invasion, T stage, and M stage. It might be owing to the differences in genetic backgrounds and the environment among different races. We also found high heterogeneity in some subgroups, because biological behavior of cancer might be affected by many possible factors during the complicated process of tumor development.

Some limitations of this meta-analysis need to be acknowledged. First, all published studies and papers were written in English, some related published or unpublished studies that met the inclusion criteria were missed. Most of the studies reported positive results, while studies of negative results were all rejected. Second, some cancers such as oral squamous cell carcinoma, gallbladder cancer, pancreatic ductal adenocarcinoma, prostate cancer, and extrahepatic bile duct carcinoma were included in only one article respectively, so we could not evaluate pooled data in subgroup analyses. Third, all of the included studies had data of the sLe^X^ expression which was detected by IHC methods. It might have some bias because of different antibodies and different standards of positive/negative sLe^X^ expression. However, it was not available for us to do a subgroup analysis to analyze the underlying bias of IHC on the pooled odds ratios or HRs. Finally, multivariate analyses were not performed on OS data in most included studies, we calculated the pooled HR only from available HRs.

In conclusion, our meta-analysis showed that a high level of sLe^X^ expression was significantly associated with lymphatic invasion, venous invasion, deep invasion, lymph node metastasis, distant metastasis, tumor stage, tumor recurrence, and OS in cancer. sLe^X^ might be a new prognostic biomarker, and it might become a new diagnostic and therapeutic target for cancer. Further studies are required to explore the molecular biological mechanisms of sLe^X^ and factors that caused significant heterogeneity in the present meta-analysis study.
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###### 

The association between sLe^X^ and cancer prognostic factors.

**Notes:** (**A**) The cancer prognostic factors which were significantly related to sLe^X^ overexpression. (a) Lymphatic invasion; (b) venous invasion; (c) T stage; (d) N stage; (e) M stage; (f) tumor stage; (g) recurrence. (**B**) The cancer prognostic factors which were not significantly related to sLe^X^ overexpression. (a) Age; (b) sex; (c) tumor size; (d) differentiation. Weights are from random effects analysis.

**Abbreviations:** RR, relative risk; CI, confidence interval; sLe^X^, sialyl Lewis X.

![](ott-9-3113Fig2)

![](ott-9-3113Fig2a)

![](ott-9-3113Fig2b)

![Meta-analysis with a random-effect model for the association of sLe^x^ overexpression with overall survival.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** HR, hazard ratio; CI, confidence interval; sLe^X^, sialyl Lewis X.](ott-9-3113Fig3){#f3-ott-9-3113}

![Begg's test results of sLe^x^ overexpression and prognostic factors.\
**Notes:** (**A**) Age; (**B**) sex; (**C**) tumor size; (**D**) differentiation; (**E**) lymphatic invasion; (**F**) venous invasion; (**G**) T stage; (**H**) N stage; (**I**) M stage; (**J**) tumor stage; (**K**) recurrence; (**L**) overall survival.\
**Abbreviations:** sLe^x^, sialyl Lewis X; SE, standard error.](ott-9-3113Fig4){#f4-ott-9-3113}

###### 

Characteristics of the included studies

  Study ID                                                  Country                      Cancer source        Number of patients   sLe^X^ expression (positive/negative)   Clinicopathological factors                                                                              Survival analysis
  --------------------------------------------------------- ---------------------------- -------------------- -------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------
  Nakamori et al[@b18-ott-9-3113] (1993)                    Japan                        Colorectal cancer    132                  50/82                                   Sex, differentiation, T stage, N stage, lymphatic invasion, venous invasion, tumor stage, recurrence     NA
  Yamaguchi et al[@b19-ott-9-3113] (1994)                   Japan                        Colorectal cancer    170                  56/114                                  Differentiation, T stage, N stage, lymphatic invasion, venous invasion, tumor stage, recurrence          NA
  Idikio[@b20-ott-9-3113] (1997)                            Canada                       Prostate cancer      [@b38-ott-9-3113]    30/8                                    Differentiation                                                                                          NA
  Nakamori et al[@b21-ott-9-3113] (1997)                    Japan                        Colorectal cancer    159                  58/101                                  Age, sex, differentiation, T stage, N stage, lymphatic invasion, venous invasion, tumor stage            NA
  Shimodaira et al[@b22-ott-9-3113] (1997)                  Japan                        Colorectal cancer    [@b43-ott-9-3113]    28/15                                   Tumor size, differentiation, T stage, N stage, lymphatic invasion, venous invasion, tumor stage          NA
  Ura et al[@b12-ott-9-3113] (1997)                         Japan                        Gastric cancer       110                  91/19                                   T stage, N stage                                                                                         NA
  Baldus et al[@b17-ott-9-3113] (1998)                      Germany                      Gastric cancer       127                  85/42                                   Sex, tumor stage                                                                                         NA
  Farmer et al[@b23-ott-9-3113] (1998)                      United States                HNSCC                82                   51/31                                   Age, sex, M stage, tumor stage                                                                           NA
  Fukuoka et al[@b11-ott-9-3113] (1998)                     Japan                        Lung cancer          52                   34/18                                   N stage, M stage                                                                                         NA
  Tatsumi et al[@b24-ott-9-3113] (1998)                     Japan                        Gastric cancer       87                   41/46                                   Differentiation, T stage, N stage, M stage, lymphatic invasion, venous invasion                          NA
  Yamaguchi et al[@b25-ott-9-3113] (1998)                   Japan                        Breast cancer        102                  61/41                                   Age, tumor size, N stage                                                                                 NA
  Kurahara et al[@b14-ott-9-3113] (1999)                    Japan                        OSCC                 70                   24/46                                   M stage                                                                                                  NA
  Takao et al[@b26-ott-9-3113] (1999)                       Japan                        EBDC                 73                   45/28                                   Age, sex, differentiation, T stage, N stage, M stage, lymphatic invasion, venous invasion, tumor stage   NA
  Futamura et al[@b27-ott-9-3113] (2000)                    Japan                        Gastric cancer       245                  135/110                                 Age, sex, differentiation, T stage, N stage, M stage, venous invasion, tumor stage                       NA
  Grabowski et al[@b28-ott-9-3113] (2000)                   Germany                      Colorectal cancer    182                  103/79                                  Sex, differentiation, T stage, N stage, M stage, tumor stage                                             Multi
  Nakagoe et al[@b16-ott-9-3113] (2000)                     Japan                        Colorectal cancer    101                  76/25                                   Tumor stage                                                                                              Uni
  Machida et al[@b29-ott-9-3113] (2001)                     Japan                        Lung cancer          [@b25-ott-9-3113]    19/6                                    Tumor size, N stage, M stage, lymphatic invasion, venous invasion                                        NA
  Takahashi et al[@b30-ott-9-3113] (2001)                   Japan                        PDAC                 [@b23-ott-9-3113]    15/8                                    NA                                                                                                       Multi
  Baldus et al[@b31-ott-9-3113] (2002)                      Germany                      Colorectal cancer    243                  165/78                                  Differentiation, N stage, M stage, tumor stage                                                           NA
  Konno et al[@b32-ott-9-3113] (2002)                       Japan                        Colorectal cancer    134                  47/87                                   N stage, M stage, venous invasion                                                                        Multi
  Nakagoe et al[@b34-ott-9-3113] (2002)                     Japan                        Breast cancer        87                   37/50                                   Age, differentiation, T stage, N stage, M stage, tumor stage                                             Multi
  Nakagoe et al[@b33-ott-9-3113],[@b34-ott-9-3113] (2002)   Japan                        Gastric cancer       101                  31/70                                   Age, sex, tumor size, differentiation, T stage, N stage, lymphatic invasion, venous invasion             Multi
  Kashiwagi et al[@b35-ott-9-3113] (2004)                   Japan                        Gallbladder cancer   54                   28/26                                   T stage, N stage, lymphatic invasion, venous invasion                                                    NA
  Yu et al[@b36-ott-9-3113] (2005)                          People's Republic of China   Lung cancer          61                   40/21                                   Age, sex, T stage, N stage, recurrence                                                                   Uni
  Faried et al[@b37-ott-9-3113] (2007)                      Japan                        ESCC                 130                  40/90                                   Sex, differentiation, T stage, N stage, M stage, lymphatic invasion, venous invasion, tumor stage        Multi
  Croce et al[@b38-ott-9-3113] (2008)                       Argentina                    HNSCC                125                  29/96                                   Age, sex, differentiation, T stage, N stage, tumor stage                                                 NA
  Sozzani et al[@b39-ott-9-3113] (2008)                     Italy                        Breast cancer        127                  37/90                                   Differentiation, T stage, N stage, venous invasion                                                       NA
  Portela et al[@b40-ott-9-3113] (2011)                     Spain                        Colorectal cancer    155                  67/88                                   Age, sex, tumor size, differentiation, T stage, N stage, M stage, tumor stage                            NA
  Schiffmann et al[@b15-ott-9-3113] (2012)                  Germany                      Colorectal cancer    215                  102/113                                 Sex, differentiation, T stage, N stage, M stage                                                          NA

**Abbreviations:** NA, not available; OSCC, oral squamous cell carcinoma; EBDC, extrahepatic bile duct carcinoma; PDAC, pancreatic ductal adenocarcinoma; Multi, Multivariate; Uni, Univariate; sLe^X^, sialyl Lewis X; ESCC, esophageal squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma.

###### 

Subgroup analyses of country

                        Number of studies   Summary RR (95% CIs)   *I*^2^ value   p~h~
  --------------------- ------------------- ---------------------- -------------- -------
  **Sex**                                                                         
  Overall               12                  0.97 (0.88, 1.07)      47.0%          0.036
  Asia                  7                   0.92 (0.80, 1.06)      56.5%          0.032
  Europe                3                   0.99 (0.83, 1.18)      0.0%           0.593
  Americas              2                   1.13 (0.95, 1.34)      24.2%          0.251
  **Tumor size**                                                                  
  Overall               5                   1.23 (0.94, 1.62)      51.1%          0.085
  Asia                  4                   1.43 (1.16, 1.77)      0.0%           0.853
  Europe                1                   0.85 (0.62, 1.16)      NA             NA
  **Differentiation**                                                             
  Overall               17                  0.94 (0.72, 1.21)      75.1%          0.000
  Asia                  11                  1.11 (0.80, 1.55)      82.3%          0.000
  Europe                4                   0.66 (0.46, 0.93)      0.0%           0.715
  Americas              2                   0.63 (0.25, 1.57)      67.8%          0.078
  **Venous invasion**                                                             
  Overall               13                  1.41 (1.18, 1.67)      52.9%          0.013
  Asia                  12                  1.49 (1.29, 1.72)      31.0%          0.143
  Europe                1                   0.69 (0.42, 1.11)      NA             NA
  **T stage**                                                                     
  Overall               18                  1.14 (1.04, 1.27)      59.6%          0.001
  Asia                  13                  1.23 (1.03, 1.47)      67.5%          0.000
  Europe                4                   1.11 (1.05, 1.19)      0.0%           0.497
  Americas              1                   0.91 (0.71, 1.17)      NA             NA
  **N stage**                                                                     
  Overall               23                  1.46 (1.29, 1.66)      55.1%          0.001
  Asia                  17                  1.53 (1.28, 1.82)      65.7%          0.000
  Europe                5                   1.40 (1.21, 1.61)      0.0%           0.724
  Americas              1                   1.23 (0.83, 1.83)      NA             NA
  **M stage**                                                                     
  Overall               14                  1.76 (1.34, 2.31)      42.1%          0.049
  Asia                  9                   2.20 (1.47, 3.30)      38.3%          0.113
  Europe                4                   1.37 (1.09, 1.72)      0.0%           0.410
  Americas              1                   0.89 (0.39, 2.05)      NA             NA
  **Tumor stage**                                                                 
  Overall               15                  1.42 (1.19, 1.68)      69.9%          0.000
  Asia                  9                   1.62 (1.24, 2.10)      69.4%          0.001
  Europe                4                   1.32 (1.10, 1.59)      22.3%          0.277
  Americas              2                   1.08 (0.79, 1.49)      58.7%          0.120

**Note:** p~h~: *P*-value for heterogeneity within each subgroup.

**Abbreviations:** RR, relative risk; CI, confidence interval; NA, not available.

###### 

Subgroup analyses of cancer types

  Subgroup                 Number of studies   Summary RR (95% CIs)   *I*^2^ value   p~h~
  ------------------------ ------------------- ---------------------- -------------- -------
  **Sex**                                                                            
  Overall                  12                  0.97 (0.88, 1.07)      47.0%          0.036
  Colorectal cancer        4                   0.92 (0.80, 1.06)      0.0%           0.978
  Gastric cancer           3                   1.12 (0.97, 1.29)      0.0%           0.981
  HNSCC                    2                   1.13 (0.95, 1.34)      24.2%          0.251
  EBDC                     1                   0.79 (0.59, 1.07)      NA             NA
  Lung cancer              1                   0.61 (0.44, 0.83)      NA             NA
  ESCC                     1                   0.96 (0.82, 1.11)      NA             NA
  **Tumor size**                                                                     
  Overall                  5                   1.23 (0.94, 1.62)      51.1%          0.085
  Colorectal cancer        2                   0.99 (0.68, 1.44)      46.7%          0.171
  Breast cancer            1                   1.38 (0.98, 1.93)      NA             NA
  Lung cancer              1                   1.42 (0.42, 4.85)      NA             NA
  Gastric cancer           1                   1.60 (1.13, 2.27)      NA             NA
  **Differentiation**                                                                
  Overall                  17                  0.94 (0.72, 1.21)      75.1%          0.000
  Colorectal cancer        8                   1.06 (0.74, 1.52)      69.6%          0.002
  Gastric cancer           3                   0.63 (0.53, 0.75)      0.0%           0.978
  Breast cancer            2                   1.07 (0.72, 1.60)      0.0%           0.548
  Prostate cancer          1                   0.87 (0.53, 1.41)      NA             NA
  EBDC                     1                   2.70 (0.84, 8.63)      NA             NA
  ESCC                     1                   1.46 (0.81, 2.64)      NA             NA
  HNSCC                    1                   0.39 (0.15, 1.01)      NA             NA
  **Lymphatic invasion**                                                             
  Overall                  10                  1.36 (1.15, 1.61)      62.3%          0.005
  Colorectal cancer        4                   1.36 (1.09, 1.68)      56.7%          0.074
  Gastric cancer           2                   1.23 (0.55, 2.73)      85.4%          0.009
  EBDC                     1                   1.31 (0.97, 1.78)      NA             NA
  Lung cancer              1                   2.53 (0.39, 16.31)     NA             NA
  Gallbladder cancer       1                   1.39 (0.92, 2.11)      NA             NA
  ESCC                     1                   1.71 (1.40, 2.08)      NA             NA
  **Venous invasion**                                                                
  Overall                  13                  1.41 (1.18, 1.67)      52.9%          0.013
  Colorectal cancer        5                   1.57 (1.33, 1.84)      0.0%           0.746
  Gastric cancer           3                   1.48 (1.04, 2.12)      35.6%          0.212
  Breast cancer            1                   0.69 (0.42, 1.11)      NA             NA
  EBDC                     1                   0.95 (0.61, 1.49)      NA             NA
  Lung cancer              1                   3.16 (0.50, 19.87)     NA             NA
  Gallbladder cancer       1                   1.05 (0.68, 1.64)      NA             NA
  ESCC                     1                   2.05 (1.48, 2.83)      NA             NA
  **T stage**                                                                        
  Overall                  18                  1.14 (1.04, 1.27)      59.6%          0.001
  Colorectal cancer        7                   1.22 (1.08, 1.38)      65.6%          0.008
  Gastric cancer           4                   1.04 (0.85, 1.28)      29.7%          0.234
  Breast cancer            2                   0.66 (0.31, 1.40)      0.0%           0.895
  EBDC                     1                   1.13 (0.79, 1.62)      NA             NA
  Lung cancer              1                   0.83 (0.66, 1.04)      NA             NA
  Gallbladder cancer       1                   1.00 (0.47, 2.14)      NA             NA
  ESCC                     1                   2.09 (1.43, 3.06)      NA             NA
  HNSCC                    1                   0.91 (0.71, 1.17)      NA             NA
  **N stage**                                                                        
  Overall                  23                  1.46 (1.29, 1.66)      55.1%          0.001
  Colorectal cancer        9                   1.54 (1.34, 1.75)      24.5%          0.226
  Gastric cancer           4                   1.28 (1.11, 1.47)      0.0%           0.393
  Breast cancer            3                   1.46 (1.04, 2.04)      41.6%          0.180
  Lung cancer              3                   2.00 (0.44, 8.97)      80.2%          0.006
  EBDC                     1                   1.06 (0.57, 1.97)      NA             NA
  Gallbladder cancer       1                   1.13 (0.56, 2.29)      NA             NA
  ESCC                     1                   2.70 (1.98, 3.68)      NA             NA
  HNSCC                    1                   1.23 (0.83, 1.83)      NA             NA
  **M stage**                                                                        
  Overall                  14                  1.76 (1.34, 2.31)      42.1%          0.049
  Colorectal cancer        5                   1.47 (1.15, 1.87)      9.2%           0.354
  Gastric cancer           2                   3.23 (1.67, 6.22)      0.0%           0.678
  Lung cancer              2                   3.21 (1.07, 9.69)      0.0%           0.871
  Breast cancer            1                   1.35 (0.20, 9.16)      NA             NA
  EBDC                     1                   1.19 (0.60, 2.37)      NA             NA
  ESCC                     1                   5.25 (2.18, 12.67)     NA             NA
  HNSCC                    1                   0.89 (0.39, 2.05)      NA             NA
  OSCC                     1                   1.24 (0.70, 2.21)      NA             NA
  **Tumor stage**                                                                    
  Overall                  15                  1.42 (1.19, 1.68)      69.9%          0.000
  Colorectal cancer        8                   1.58 (1.36, 1.82)      13.0%          0.328
  Gastric cancer           2                   1.11 (0.88, 1.39)      19.5%          0.265
  HNSCC                    1                   1.08 (0.79, 1.49)      58.7%          0.120
  Breast cancer            1                   0.90 (0.27, 2.97)      NA             NA
  EBDC                     1                   1.12 (0.74, 1.70)      NA             NA
  ESCC                     1                   3.04 (1.95, 4.73)      NA             NA

**Note:** p~h~: *P*-value for heterogeneity within each subgroup.

**Abbreviations:** RR, relative risk; CI, confidence interval; HNSCC, head and neck squamous cell carcinoma; OSCC, oral squamous cell carcinoma; EBDC, extrahepatic bile duct carcinoma; ESCC, esophageal squamous cell carcinoma; NA, not available.
